Drug Profile
AB 171
Alternative Names: AB171; LA 419Latest Information Update: 29 Jul 2022
Price :
$50
*
At a glance
- Originator Lacer
- Developer ARCA biopharma Inc; Lacer
- Class Furans; Heart failure therapies; Organic nitrates; Small molecules; Sugar alcohols; Vascular disorder therapies
- Mechanism of Action Antioxidants; Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Chronic heart failure; Peripheral arterial disorders
- Discontinued Ischaemic heart disorders
Most Recent Events
- 27 Jul 2022 Lacer has been acquired by Italfarmaco
- 28 Dec 2021 No recent reports of development identified for preclinical development in Chronic-heart-failure in USA
- 28 Dec 2021 No recent reports of development identified for preclinical development in Peripheral-arterial-disorders in USA